Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
At the time the article was last revised Daniel J Bell had no financial relationships to ineligible companies to disclose.View Daniel J Bell's current disclosures
Aplastic anemia is a rare hematopoietic stem-cell disorder. The condition results in pancytopenia and hypocellular bone marrow. Most cases are acquired, however, there are unusual inherited forms.
On this page:
Aplastic anemia manifests as a marked reduction in the number of pluripotent hematopoietic stem cells. It is immune-mediated in most cases where autoreactive lymphocytes mediate the destruction of hematopoietic stem cells. Environmental exposures (e.g. drugs, viruses, and toxins) are thought to initiate the aberrant immune response in some patients, but most cases are classified as idiopathic.
Signal characteristics follow differences in fatty versus hematopoietic marrow. Reported patterns include 3:
focal low-signal (both TI and T2) areas (likely representing islands of active hematopoietic cells) interspersed with high-SI areas in the marrow of the spine. Note this pattern is also seen in lymphoma, metastases and myeloma.
diffuse high-signal marrow without focal abnormalities in the pelvis and proximal femoral regions
MRI is also useful for assessment of response to treatment in aplastic anemia as well as other hematopoietic disorders 4.
Treatment and prognosis
Similar to other autoimmune diseases, aplastic anemia has a varied clinical course which ranges from some patients having mild symptoms that necessitate little or no therapy to others presenting with life-threatening pancytopenia. Acquired aplastic anemia can be effectively treated by allogeneic bone-marrow transplantation, immunosuppression (generally anti-thymocyte globulin and cyclosporine), and high-dose cyclophosphamide.
development of paroxysmal nocturnal hemoglobinuria (PNH)
development of myelodysplastic syndrome
- 1. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 365 (9471): 1647-56. doi:10.1016/S0140-6736(05)66515-4 - Pubmed citation
- 2. Teramura M, Mizoguchi H. Special Education: Aplastic Anemia. Oncologist. 1996;1 (3): 187-189. Oncologist (full text) - Pubmed citation
- 3. Kaplan PA, Asleson RJ, Klassen LW et-al. Bone marrow patterns in aplastic anemia: observations with 1.5-T MR imaging. Radiology. 1987;164 (2): 441-4. Radiology (abstract) - Pubmed citation
- 4. Mckinstry CS, Steiner RE, Young AT et-al. Bone marrow in leukemia and aplastic anemia: MR imaging before, during, and after treatment. Radiology. 1987;162 (3): 701-7. Radiology (abstract) - Pubmed citation
- 5. Helms CA, Major NM, Anderson MW et-al. Musculoskeletal MRI E-Book. Saunders. (2008) ISBN:1437720919. Read it at Google Books - Find it at Amazon
- 6. Gupta G, Robertson P, Szer J. Focal lesions on magnetic resonance imaging in aplastic anaemia: multiple metastases or haemopoietic marrow. Australas Radiol. 2007;51 Spec No. B110-4. doi:10.1111/j.1440-1673.2007.01830.x - Pubmed citation
- 7. De Mola RL, Kurre P. MRI findings in aplastic anemia. American journal of hematology. 84 (11): 754. doi:10.1002/ajh.21394 - Pubmed
- 8. Park J, Jun J, Kim Y, Lee J, Kim C, Hahn S. Osteonecrosis of the hip in patients with aplastic anemia. Journal of Korean medical science. 17 (6): 806-10. doi:10.3346/jkms.2002.17.6.806 - Pubmed
- 9. Biswajit H, Pratim PP, Kumar ST, Shilpi S, Krishna GB, Aditi A. Aplastic anemia: a common hematological abnormality among peripheral pancytopenia. North American journal of medical sciences. 4 (9): 384-8. doi:10.4103/1947-2714.100980 - Pubmed